Cited 4 times in
Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜인 | - |
dc.contributor.author | 서석교 | - |
dc.contributor.author | 선기은 | - |
dc.date.accessioned | 2022-12-22T04:38:42Z | - |
dc.date.available | 2022-12-22T04:38:42Z | - |
dc.date.issued | 2022-10 | - |
dc.identifier.issn | 1369-7137 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/192183 | - |
dc.description.abstract | Objective: This study aimed to investigate the relationship between hormone replacement therapy (HRT) types and breast cancer (BC) incidence in postmenopausal women in Korea. Methods: The nested case-control study used data from the National Health Insurance Service database. Among the women aged ≥50 years who menopaused between 2004 and 2007, BC incidence up to 2017 was analyzed in 36,446 women using or having used HRT for >1 year and in 36,446 women who did not use any HRT for more than 1 year. HRT types and duration were classified into three categories. Results: BC risk (BCR) decreased with tibolone use for all ages. With HRT initiation in women aged ≥50 years, BCR was lower with tibolone and estrogen-progestogen therapy. HRT for <3 years showed lower BCR with tibolone, while higher BCR was observed with estrogen-only therapy. BCR was lower in women of all ages on HRT for >5 years than in the control group. Conclusions: For women in their 50s, tibolone use lowers BCR; for all ages, the use of any HRT for >5 years showed lower BCR in Korea. These divergent results from western countries could be associated with the specific characteristics of BC in Korea. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Informa Healthcare | - |
dc.relation.isPartOf | CLIMACTERIC | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Breast Neoplasms* / chemically induced | - |
dc.subject.MESH | Breast Neoplasms* / epidemiology | - |
dc.subject.MESH | Case-Control Studies | - |
dc.subject.MESH | Child, Preschool | - |
dc.subject.MESH | Estrogen Replacement Therapy* / adverse effects | - |
dc.subject.MESH | Estrogen Replacement Therapy* / methods | - |
dc.subject.MESH | Estrogens | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hormone Replacement Therapy / adverse effects | - |
dc.subject.MESH | Hormone Replacement Therapy / methods | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Incidence | - |
dc.subject.MESH | Republic of Korea / epidemiology | - |
dc.title | Relationship between the type of hormone replacement therapy and incidence of breast cancer in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics and Gynecology (산부인과학교실) | - |
dc.contributor.googleauthor | J K Baek | - |
dc.contributor.googleauthor | H I Kim | - |
dc.contributor.googleauthor | M J Kang | - |
dc.contributor.googleauthor | K E Seon | - |
dc.contributor.googleauthor | E H Kim | - |
dc.contributor.googleauthor | S K Seo | - |
dc.identifier.doi | 10.1080/13697137.2022.2077096 | - |
dc.contributor.localId | A05969 | - |
dc.contributor.localId | A01888 | - |
dc.relation.journalcode | J00542 | - |
dc.identifier.eissn | 1473-0804 | - |
dc.identifier.pmid | 35674251 | - |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.1080/13697137.2022.2077096 | - |
dc.subject.keyword | Breast cancer | - |
dc.subject.keyword | hormone replacement therapy | - |
dc.subject.keyword | incidence | - |
dc.subject.keyword | menopause | - |
dc.subject.keyword | postmenopausal | - |
dc.subject.keyword | tibolone | - |
dc.contributor.alternativeName | Kim, Hye In | - |
dc.contributor.affiliatedAuthor | 김혜인 | - |
dc.contributor.affiliatedAuthor | 서석교 | - |
dc.citation.volume | 25 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 516 | - |
dc.citation.endPage | 522 | - |
dc.identifier.bibliographicCitation | CLIMACTERIC, Vol.25(5) : 516-522, 2022-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.